About Argos Therapeutics
Argos Therapeutics is a Healthcare company based in Durham (United States) founded in 1997, and was acquired by Genexine in February 2019. An online gambling platform is operated for Tai Xiu games. It operates on a Commission-Based model. Argos Therapeutics has raised $169.65 million across 15 funding rounds from investors including SVB, ABN AMRO and Edelman Financial Engines. The company has 40 employees. Argos Therapeutics offers products and services including Tai Xiu Online. Its focus areas include Entertainment, Gambling and Online Casinos. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
A platform for online Tai Xiu gambling is provided by Argos Therapeutics. Various betting options and promotional offers are featured for users. The service targets players in Vietnam and other regions with a focus on secure transactions. Multiple payment methods including cryptocurrency are supported for user convenience. The platform is designed to cater to a growing community of online gamblers.
- Headquarters Durham, United States
- Employees 40
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website argostherapeutics.com
- Social LinkedIn X
- Acquired by Genexine (Feb 2019)
- Annual Revenue$1.9 M (USD)101as on Dec 31, 2017
- Net Profit-$40.58 M (USD)23as on Dec 31, 2017
- EBITDA-$62.46 M (USD)-19as on Dec 31, 2017
- Total Equity Funding$169.65M (USD)
in 15 rounds
- Latest Funding Round$6M (USD), Post-IPO
Jun 2017
- InvestorsSVB
& 29 more
- Employee Count40
- Acquired byGenexine
(Feb 2019)
Products & Services of Argos Therapeutics
Argos Therapeutics offers a comprehensive portfolio of products and services, including Tai Xiu Online.
Online Tai Xiu game platform is provided for users.
Funding Insights of Argos Therapeutics
Argos Therapeutics has successfully raised a total of $169.65M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $169.65M
- Total Rounds 15
- Last Round Post-IPO — $6M
- First Round $1.6M
(Jun 2000)
- Investors Count 28
Latest 10 of 15 funding rounds of Argos Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2017 | $6M | Post-IPO | – | – | – |
| Mar 2016 | Post-IPO | – | – | ||
| Apr 2015 | $10M | Post-IPO | – | – | – |
| Apr 2015 | $6.6M | Grant | – | – | |
| Nov 2013 | $17.5M | Series E | – | – | |
| Aug 2013 | $42.5M | Series E | – | Pharmstandard International | |
| Apr 2012 | $25M | Series D | – | Forbion | |
| Jul 2011 | $3.5M | Series C | – | – | – |
| Sep 2010 | $4.85M | Series C | – | – | – |
| Apr 2008 | $35.2M | Series C | – | – |
30 investors in total: 30 institutional.
Investors in Argos Therapeutics
Argos Therapeutics has secured backing from 30 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, ABN AMRO and Edelman Financial Engines.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
Lumira Ventures is engaged in life sciences venture capital investment. | lumiraventures.com | Toronto, Canada | ||
Early-stage life sciences and tech focused VC firm funding companies in the US | intersouth.com | Durham, United States | ||
Investment strategies are provided across diverse asset classes and markets. | 1965 | cdpq.com | Quebec City, Canada | |
| aurorafunds.com | ||||
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
| mizuho-vc.co.jp | ||||
Private equity platform is operated for investing in growth-oriented companies. | 1981 | jaic-vc.co.jp | Tokyo, Japan | |
| genechem.com |
Investor details for Argos Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Argos Therapeutics
15 people are tracked at Argos Therapeutics (5 in leadership, 10 in board & advisors); the tracked headcount is 40.
| Name | Role | Group |
|---|---|---|
Frederick M. Miesowicz | COO | Leadership |
Charles A. Nicolette | Chief Scientific Officer & VP, Research & Development | Leadership |
Lori R. Harrelson | VP, Finance | Leadership |
Doug Plessinger | VP, Clinical & Medical Affairs | Leadership |
Jeffrey D. Abbey | President & CEO | Leadership |
Jean Lamarre | Director | Board & advisors |
Alexey Vinogradov | Director | Board & advisors |
Robert F. Carey | Director | Board & advisors |
Hubert Birner | Chairman | Board & advisors |
Philippe Van Holle | Director | Board & advisors |
Philip R. Tracy | Director | Board & advisors |
Andrei Petrov | Director | Board & advisors |
Brian J. Underdown | Director | Board & advisors |
Sander van Deventer | Director | Board & advisors |
David W. Gryska | Director | Board & advisors |
Complete people profiles for Argos Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Argos Therapeutics
5 dated milestones of Argos Therapeutics across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Argos Therapeutics is founded.
- Funding First funding round of $1.6M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $6.0M.
- Exit Acquired by Genexine.
Competitors of Argos Therapeutics
Argos Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Argos Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Argos Therapeutics
Websites that share an audience with Argos Therapeutics (argostherapeutics.com).
Websites whose visitors overlap most with Argos Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| edgetherapeutics.com | 100% | View details | |||
| tgtherapeutics.com | 99% | 29.4K | #1,758,849 | View details | |
| addextherapeutics.com | 99% | 3.3K | #7,605,013 | View details | |
| onconova.com | 99% | View details | |||
| esperion.com | 98% | 16.4K | #1,899,294 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Argos Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Argos Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Argos Therapeutics
Complete news archive for Argos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Argos Therapeutics
Argos Therapeutics was founded in 1997 and raised its 1st funding round 3 years after it was founded.
Argos Therapeutics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Argos Therapeutics is a funded company, having raised a total of $169.65M across 15 funding rounds to date. The company's 1st funding round was a Series C of $35.2M, raised on Jun 2000.
Argos Therapeutics has 40 employees.
Annual revenue of Argos Therapeutics is $1.9M as on Dec 31, 2017.
A platform for online Tai Xiu gambling is provided by Argos Therapeutics. Various betting options and promotional offers are featured for users. The service targets players in Vietnam and other regions with a focus on secure transactions. Multiple payment methods including cryptocurrency are supported for user convenience. The platform is designed to cater to a growing community of online gamblers.
Argos Therapeutics offers Tai Xiu Online.
Argos Therapeutics has 30 investors. Key investors include SVB, ABN AMRO, Edelman Financial Engines, NIH, and BD.
Yes. Argos Therapeutics was acquired by Genexine in February 2019.